Hepatic artery chronomodulated infusion of irinotecan, 5-fluorouracil and oxaliplatin against liver metastases in heavily pretreated patients with colorectal cancer.

被引:0
|
作者
Bouchahda, M
Tanaka, K
Adam, R
Giacchetti, S
Brézault-Bonnet, C
Gholam, D
Kunslinger, F
Castaing, D
Jasmin, C
Lévi, FA
机构
[1] Hop Paul Brousse, Villejuif, France
[2] INSERM, E0354, Villejuif, France
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
3722
引用
收藏
页码:299S / 299S
页数:1
相关论文
共 50 条
  • [1] Combination of irinotecan, oxaliplatin and 5-fluorouracil as a rechallenge regimen for heavily pretreated metastatic colorectal cancer patients
    Fernandes G.D.S.
    Braghiroli M.I.
    Artioli M.
    Paterlini A.C.C.R.
    Teixeira M.C.
    Gumz B.P.
    Girardi D.M.
    Braghiroli O.F.M.
    Costa F.P.
    Hoff P.M.
    Journal of Gastrointestinal Cancer, 2018, 49 (4) : 470 - 475
  • [2] Effective salvage therapy of liver-only colorectal cancer metastases with chronomodulated irinotecan-fluorouracil-oxaliplatin via hepatic artery infusion.
    Bouchahda, M.
    Adam, R.
    Giacchetti, S.
    Li, X. M.
    Castaing, D.
    Gholam, D.
    Kunstlinger, F.
    Jasmin, C.
    Machover, D.
    Lévi, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 167S - 167S
  • [3] Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study
    Levi, Francis
    Karaboue, Abdoulaye
    Etienne-Grimaldi, Marie-Christine
    Paintaud, Gilles
    Focan, Christian
    Innominato, Pasquale
    Bouchahda, Mohamed
    Milano, Gerard
    Chatelut, Etienne
    CLINICAL PHARMACOKINETICS, 2017, 56 (02) : 165 - 177
  • [4] Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study
    Francis Lévi
    Abdoulaye Karaboué
    Marie-Christine Etienne-Grimaldi
    Gilles Paintaud
    Christian Focan
    Pasquale Innominato
    Mohamed Bouchahda
    Gérard Milano
    Etienne Chatelut
    Clinical Pharmacokinetics, 2017, 56 : 165 - 177
  • [5] Hepatic Arterial Infusion of Irinotecan, 5-Fluorouracil and Leucovorin in Patients with Liver Metastases from Colorectal Carcinoma
    Melichar, Bohuslav
    Voboril, Zbynek
    Krajina, Antonin
    Malirova, Eva
    Weiner, Pavel
    Nova, Marketa
    Ryska, Ales
    Dvorak, Josef
    ANTICANCER RESEARCH, 2012, 32 (12) : 5487 - 5493
  • [6] Hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma
    Melichar, B.
    Ferko, A.
    Krajina, A.
    Rouskova, L.
    Dvorak, J.
    Svebisova, H.
    Neoral, C.
    Koecher, M.
    Malirova, E.
    Paral, J.
    JOURNAL OF BUON, 2012, 17 (04): : 677 - 683
  • [7] Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
    Garufi, C.
    Torsello, A.
    Tumolo, S.
    Ettorre, G. M.
    Zeuli, M.
    Campanella, C.
    Vennarecci, G.
    Mottolese, M.
    Sperduti, I.
    Cognetti, F.
    BRITISH JOURNAL OF CANCER, 2010, 103 (10) : 1542 - 1547
  • [8] Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
    C Garufi
    A Torsello
    S Tumolo
    G M Ettorre
    M Zeuli
    C Campanella
    G Vennarecci
    M Mottolese
    I Sperduti
    F Cognetti
    British Journal of Cancer, 2010, 103 : 1542 - 1547
  • [9] Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
    I Chau
    A Webb
    D Cunningham
    M Hill
    J S Waters
    A Norman
    A Massey
    British Journal of Cancer, 2001, 85 : 1258 - 1264
  • [10] Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
    Chau, I
    Webb, A
    Cunningham, D
    Hill, M
    Waters, JS
    Norman, A
    Massey, A
    BRITISH JOURNAL OF CANCER, 2001, 85 (09) : 1258 - 1264